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background: The 2013 AHA/ACC cholesterol treatment guidelines recommend consideration of statin therapy based on an estimated 10-
year atherosclerotic cardiovascular disease (ASCVD) risk score ≥7.5%. Previous guidelines suggest statin use for Reynold’s Risk Score 
(RRS) ≥10%. We compared the ASCVD risk and RRS Model A and B to assess agreement between treatment thresholds.
Methods: Data from 660 female patients (pts), ages 40 to 79 years, from 2006-2014 at Rush and Emory University Heart Centers for 
Women were evaluated. Pts’ total, LDL and HDL cholesterol levels, ApoB, Lp(a), HS-CRP, HbA1c, history of diabetes, current smoking, 
family history, hypertension, and treatment were collected. HDL was substituted for ApoA in RRS. Agreement between RRS and ASCVD 
risk score was evaluated using Bland-Altman plot, McNemar’s and Chi-square tests.
Results: RRS-A and ASCVD risk have a highly significant agreement using the Bland Altman plot at low-risk levels, but agreement 
diminished with increased risk. See Figures.
conclusion: Discrepancies in scoring result from Lp(a), HS-CRP, diabetes treatment, and family history inclusion in RRS, while ethnicity 
and HTN treatment are included in ASCVD. We propose that while high ASCVD risk scores may identify pt populations that benefit from 
pharmacologic intervention, pts categorized as low-risk by ASCVD risk score but intermediate to high-risk by RRS may also benefit from 
aggressive risk factor modification.
 
